RU2582971C2 - Method of treating neurosis - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to neurology. What is presented is a method of treating neurosis, which involves using mechanically activated amorphous gluconic acid calcium salt with homogenous diffuse halo in its X-ray powder diffraction pattern characterised by gravity centre line displacement of an absorption band of 3000-3600 cm^-1 to a greater wave number range by a value of no more than 200 cm^-1, presence of an absorption band at frequencies 3308±20, 2933±10, 1602±10, 1420±10 with an arm of 1260±40, 1085±10, 1044±10, 877±10, 682±10, 577±10 cm^-1 and a secondary absorption band at frequencies 947±10 cm^-1 in the IR spectrum, a decrease in endothermic peaks in the temperature range of 125-165°C and a peak increase in the temperature range of 30-100°C as shown by differential thermal analysis, presence of an intensive single line with a splitting factor from 2.000 to 2.006 and a width from 8 to 9 E in the electron paramagnetic resonance spectrum, a manifestation of an unresolved fine-structure broad line within the range of 60-90 and 170-190 mln^-1 in ¹³C NMR spectra, resonant line displacement of their aquatic solutions within the range of 62.8-179.2 mln^-1 by a value of no more than 0.1 mln^-1 in ¹³C NMR spectra, resonant line displacement of their aquatic solutions within the range of 1.2-4.95 mln^-1 by a value of no more than 0.02 mln^-1 in ¹H NMR spectra, an increase of peak intensities 160 t/g of mass spectra of at least 2.5 times as much and peak intensities 780-1000 t/g of ethanolic extracts of their solutions of at least three times as much in mass spectrometric analysis. The above amorphous gluconic acid calcium salt is administered orally once to four times a day in doses 0.5-2.0 g for 30-40 days every 1-2 weeks in the form of powder, and/or tablets, and/or capsule, and/or solution, until remission is achieved.

EFFECT: recovery of normal functioning of nerve cells and enables avoiding the use of anxiolytics, antidepressants or neuroleptics.

4 ex

Description

The invention relates to medicine, in particular to neurology, in particular to the treatment of neurosis and is aimed at reducing the development of pathological conditions, such as various manifestations of neurosis: neurotic, obsessive-compulsive, dissociative disorders.

There is a method of complex treatment of neurosis [1], in which tranquilizers, antidepressants, antipsychotics are used as basic drug therapy, B-adrenergic blockers, adaptogens, multivitamin complexes, dehydration drugs, psychotherapy, social and professional adaptation methods, physical therapy, balneotherapy are additionally used, reflexology, various types of physiotherapy.

The disadvantages of the methods of drug therapy [1-4], in addition to the low effectiveness of the therapeutic effect, are the known duration of treatment, the need to change the conditions of the social environment, the uncertainty in the timing of achieving a positive effect, the occurrence of drug dependence on a number of drugs, side effects of the drugs used. As well as the development of intolerance to drugs and in this regard, the rejection of their intake.

There is another method for the treatment of neurosis [5], which additionally includes the introduction of official liquid 5% -10% solutions of dosage forms of calcium preparations by electrophoresis in complex treatment.

The disadvantages of this method, taken as a prototype, is that the additional introduction to the complex therapy of official liquid 5% -10% solutions of dosage forms of calcium preparations by electrophoresis does not significantly increase the effectiveness of the treatment. At the same time, there remain problems of the emergence of drug dependence on basic drug therapy (tranquilizers, antidepressants, antipsychotics, etc.), side effects and the development of intolerance to the drugs used. The calcium preparations used are not used as basic therapy and are not considered due to the lack of any significant effectiveness due to their low digestibility in the treatment of neurosis.

The purpose of the invention is to increase the effectiveness of the treatment of neurosis, reduce the duration of treatment, achieve a stable remission of the pathological condition, minimize side effects from medications on other organs, and prevent drug dependence.

The problem is solved in that in the method of treating neurosis, mechanically activated calcium salt of gluconic acid in an amorphous state with particle sizes not exceeding 1 μm is used orally 1-4 times a day in doses of 0.5-2.0 grams as the basic therapy, courses of 30-40 days with interruptions in the application of 1-2 weeks, until remission.

The use of the calcium salt of gluconic acid in an amorphous state with particle sizes not exceeding 1 μm as the basic therapy allows, due to the assimilation of calcium ions by the body's cells, the nutrition of dystophically affected cells. This advantage is due to the ability of a mechanically activated calcium salt of gluconic acid in an amorphous state with particle sizes not exceeding 1 μm to penetrate through the affected calcium channels of the cell membrane and to ensure the transport of calcium and glucose ions into the cell.

At the same time, a dose of 0.5-2.0 grams ensures the restoration of normal activity of the nerve cells of the body and the additional use of recovery procedures leads to a unique positive clinical effect that has no world analogues.

In addition, the proposed method eliminates the use of drugs that affect the central nervous system (tranquilizers, antidepressants, antipsychotics, etc.).

The method is implemented as follows.

Orally 1-4 times a day in doses of 0.5-2.0 grams, courses of 30-40 days with interruptions in use for 1-2 weeks, until remission.

The following are clinical examples of a specific implementation of the proposed method of treatment.

Example 1. Patient A., 42 years old, an employee of law enforcement agencies with symptoms of rapid mental and physical fatigue, lack of vigor and poor tolerance of the usual work regime before the disease; almost constant moderate intensity of a compressive headache in the form of a hoop and worsening of normal sleep (it is difficult to fall asleep, often wakes up at night, and in the morning there is no feeling of rest); increased irritability, mood instability with a feeling of accomplishment of something bad (scary), poor tolerance of loud sounds, bright light, a tendency to lower blood pressure to 90-100 / 70 mm Hg, periodic unpleasant sensations in the heart.

He fell ill 4 months ago, during the second business trip to the area of local hostilities. The above symptoms developed gradually and are associated with constant mental stress, disorder in life, and frequent stressful situations.

Complex medical treatment with the most effective neurological drugs in combination with physiotherapy and psychotherapy for 2.5 months did not lead to an improvement in the condition.

Objectively: In somatic status without pathology. In the neurological status, individual scattered neurological signs are detected (convergence of the eyeballs, softer right nasolabial fold, uniform revitalization of deep reflexes from the limbs, small tremor of fingers of outstretched hands without impaired function), A / D 100/70 mm Hg. heart rate 78 beats in minutes, anxiety-depressive manifestations with irritable weakness.

The headache severity index according to the visual-analogue scale (VAS) is 6.0 cm. The severity of symptoms of autonomic dystonia according to the Wayne score table (S.V.D.) is 42 points. Spielberger scale: L.T. (personal anxiety) - 36 points, R.T. (reactive anxiety) - 44 points, test 10 words - direct reproduction - 8 words, delayed reproduction (after 1 hour) - 7 words.

The clinical diagnosis is neurasthenia (hyposthenic form) with a chronic moderately severe cephalgic syndrome (tension, dissomnia, and permanent syndrome of vegetovascular dystonia).

The mechanically activated calcium salt of gluconic acid was treated in an amorphous state with particle sizes not exceeding 1 μm, orally, 2 times a day, doses of 2.0 grams, 2 courses of 40 days, with interruptions in use for 1 week.

As a result of treatment, the condition improved significantly: the headache almost disappeared, night sleep normalized, general health and mood improved, and physical and mental performance was restored.

In neurological status without focal neurological symptoms A.D. - 120/80 mm Hg, pulse 76 beats. per min, the cephalgia indicator on the YOUR scale is 4 cm. The severity of vegetative symptoms on the Wayne scale (SVD) is 28 points, the Spielberger scale: L.T. (personal anxiety) - 32 points, R.T. (reactive anxiety) - 34 points. Test of 10 words: direct reproduction - 8 words, delayed (after 1 hour) - 8 words.

As a result of treatment in patient A., 42 years old, the clinical manifestations of neurasthenia were substantially completely regressed. The indicators of V.A.Sh. (visual-analogue scale), therefore, the severity of the headache decreased, the severity of the autonomic dystonia syndrome (according to the Wayne table) decreased, and the indicators of reactive and personal anxiety on the Spielberger scale significantly improved. The patient took up his duties.

Thus, the treatment of this patient according to the method in a relatively short time and with minimal effort has led to a pronounced and persistent positive therapeutic effect.

Example 2. Patient K., 38 years old, an employee of law enforcement agencies with symptoms of increased irritability, restraint, an almost constant sensation of internal tension and discomfort, poor sleep; constant significantly expressed compressive nature of the headache in the crown of the head, dizziness at times, unstable blood pressure with a tendency to increase to 140/90 mm Hg, periodic unpleasant sensations from the heart and stomach, periodically occurring attacks in the form of a pronounced fear of death, increase in blood pressure up to 160/90 mm Hg, internal chills, sensation of lack of air with frequent urination at the end. A three-month course of treatment in the neurological department, the rehabilitation department, and then the sanatorium passed without much success.

Objectively: no somatic diseases were detected.

In neurological status: the right nasolabial fold is flattened. Small tremor of fingers of outstretched arms. Dermographism is red, spilled. Blood pressure 140/80 mm Hg, pulse 68 beats. in minutes Emotionally tense, anxiety-depressive manifestations. Symptom Tail. The severity of headache on a visual-analogue scale (V.A.S.) is 5.2 cm. The severity of symptoms of autonomic dystonia on the Wayne scale (SVD) is 38 points. Spielberger scale: L.T. (personal anxiety) - 40 points, R.T. (reactive anxiety) - 46 points. Test 10 words: direct playback - 7 words, delayed playback (after 1 hour) - 6 words.

Clinical diagnosis: Neurasthenia (hypersthenic form) with chronic moderate cephalgic syndrome (tension), dysomnia, permanent-paroxysmal syndrome of vegetovascular dystonia, panic attacks, with a frequency of 1-3 times a month.

The mechanically activated calcium salt of gluconic acid was treated in an amorphous state with particle sizes not exceeding 1 μm, orally, 2 times a day, doses of 2.0 grams, 2 courses of 30 days, with interruptions in use for 1 week.

After 70 days of treatment, the attacks of panic attacks gradually stopped, headaches disappeared, sleep normalized. Blood pressure stabilized (130/80 mm Hg), mood and well-being improved significantly.

Objectively: the right nasolabial fold is softer, red dermographism. Fully oriented, adequate to handle. The severity of the headache (V.A.S. indicator) - 3.2 cm. The severity of vegetative symptoms according to the Wayne table (S.V.D.) - 34 points. Spielberger scale: L.T. (personal anxiety) - 32 points, R.T. (reactive anxiety) - 30 points. Test of 10 words: immediate and delayed (after 1 hour) reproduction of 8 words.

As a result of treatment with gluconic acid calcium salt according to RF patent No. 2268053, headaches disappeared in a patient with a hypersthenic form of neurasthenia, sleep was normalized, panic attacks gradually disappeared. The indicators of V.A.Sh. (visual-analogue scale), indicators of personal and reactive anxiety (L.T. and R.T.) on the Spielberger scale. The severity of the syndrome of autonomic dystonia (S.V.D.) on the scale of Wayne decreased. Recommended to start on duty. Thus, the inventive technique was effective in hyposthenic and hypersthenic forms of neurasthenia.

Example 3. Patient B., 32 years old, accountant with complaints of self-doubt, emotional vulnerability, suspiciousness, fear of a serious organic heart disease, or the possibility of cancer from the digestive system. Frequent obsessive memories (up to 10 times a day) of one and the same difficult life situation with a threat to life that really happened about 2 years ago. Troubled sleep with nightmares. Repeatedly underwent treatment in a neurological clinic with the use of complex therapy, is monitored by a neurologist, receives constantly outpatient treatment (courses of tranquilizers, antidepressants, antipsychotics).

Objectively: asthenic physique, from the side of internal organs without pathological changes.

Neurological status without focal neurological symptoms. Psychoasthenic traits of character. Small tremor of the head when fixing the gaze, A.D. - 100/60 mm Hg pulse 72 beats per min. The severity of headache - an indicator V.A.S. (visual-analogue scale) - 4.2 cm severity of vegetative symptoms according to the Wayne table (S.V.D.) - 30 points. Spielberger L.T. scale: (personal anxiety) - 38 points, R.T. (reactive anxiety) - 32 points. Test of 10 words: direct reproduction of 9 words, delayed reproduction (after 1 hour) - 8 words. Clinical diagnosis: neurotic obsessive-compulsive disorder with phobias (cardiophobia and carcinophobia), obsessive conditions (repeat film session), rhizoidal cephalgic syndrome (venous type), psychoasthenic syndrome of vegetative-vascular dystonia with arterial hypotension.

The mechanically activated calcium salt of gluconic acid was treated in an amorphous state with particle sizes not exceeding 1 μm, orally, 2 times a day, doses of 2.0 grams, 3 courses of 30 days, with interruptions in use for 1 week. After a course of treatment, cardiophobia almost disappeared, obsessive memories (a second film session) became rare (once every 2-3 months) and erased. Significantly improved sleep, general mood and well-being. He plans to start work in the near future. The severity of the headache (V.A.S. indicator) - 4.2 cm, the severity of vegetative symptoms on the Wayne scale (S.V.D.) - 26 points. Spielberger scale: L.T. (personal anxiety) - 34 points, RT (reactive anxiety) -28 points. 10-word test: immediate and delayed reproduction of 9 words.

Thus, patient B., 32 years old, with neurotic obsessive-compulsive disorder, as a result of the course of treatment, significantly improved overall well-being and mood. Phobias disappeared, night sleep almost completely normalized. Feels almost healthy. Used indicators of the severity of autonomic symptoms (S.V.D. according to Wayne's table); personal and reactive anxiety (L.T. and R.T.) on the Spielberger scale improved significantly. Almost complete recovery. Thus, the removal of the patient from a pathological condition disturbed by a strong stress factor was achieved after a course of treatment according to the method.

Example 4. Patient V., 26 years old, an employee of law enforcement agencies with complaints of weakness in the left limbs, gait changes, impaired sensitivity on the left side of the body, general weakness, difficulty swallowing with a sensation of a lump in the throat, hoarse voice, sometimes complete loss of voice, frequent dizziness, at times for no apparent reason, visual impairment, sensation of veil before the eyes. Sick for about 2 months. He was treated in a hospital without effect, directed to treatment at the place of residence.

Objectively: pathology from the side of internal organs is not revealed.

In neurological status: left-side functionally neurological hemiparesis, hemiparetic gait when walking, Wernicke-Mans posture. When checking the range of motion, the free inclusion of (paralyzed) left limbs, integral motor acts, freely bends and extends the limbs in large and small joints. However, on command to stand up, he immediately takes the pose of Wernicke-Mans, demonstrates a hemiparetic gait. Muscle tone in the limbs is not impaired. Deep reflexes from the upper and lower extremities of medium vivacity, equal. Pathological symptoms are not determined. Abdominal reflexes are alive. When checking sensitivity, it gives left-sided hyposthesia with a border strictly in the midline. Dystonia, sometimes when standing. HELL 120/80 mm Hg, pulse 72 beats. in minutes The finger-nasal test satisfactorily performs in the Romberg position. Blood and urine tests are normal, the fundus is not broken, according to MRI, the brain is without pathological changes. ENT consultation: paresis of the left vocal cord. EEG without pathological changes. The severity of headache (V.A.S. scale) - 3.2 cm Spielberger scale: L.T. (personal anxiety) -38 points, R.T. (reactive anxiety) - 36 points. The severity of autonomic symptoms on the Wayne scale (S.V.D.) - 32 points. Test 10 words - play 8 words. Immediate delayed playback (after 1 hour - 6 words).

Clinical diagnosis: neurotic conversion disorder with functional neurological left-sided hemiparesis, left hyposthesia with transient dysphonia and aphonia.

The mechanically activated calcium salt of gluconic acid was treated in an amorphous state with particle sizes not exceeding 1 μm, orally, 2 times a day, doses of 2.0 grams, 3 courses of 30 days, with interruptions in use for 1 week.

As a result of treatment, the conversion manifestations of hemiparesis and hemihyposthesia were completely eliminated, gait and speech were normalized, and feels almost healthy. Scale V.A.S. - 3.2 cm, Spielberger scale: L.T. (personal anxiety) - 28 points, reactive anxiety (RT) - 28 points. The severity of autonomic symptoms on the Wayne scale (S.V.D.) - 32 points. Test 10 words - play 8 words. Immediate delayed playback (after 1 hour) - 8 words.

The conversion manifestation of hemiparesis, hemihyposthesia, dysphonia disappeared, indicators of personal and reactive anxiety on Spielberger’s scale decreased, in neurological status without focal symptoms. Recognized as continuing to serve as a contractor.

Thus, the application of the proposed method for the treatment of neurosis, with known difficulties that can be corrected by existing methods, allows to achieve high efficiency therapy with stable remission in a short time and at minimal cost, as well as completely eliminate the risk of drug dependence on psychotropic drugs. In the age range from 18 to 80 years, there were no complications and adverse effects of the proposed method of treatment.

Information sources:

1. Wayne A.M., Dyukova G.M., Vorobyova O.V. etc. Panic attacks (neurological and psychophysiological aspects). St. Petersburg: Institute of Medical Marketing, 1997. 304 p.

2. A.M. Wayne. Pain syndromes in neurological practice M .: MEDpress-inform, 2001.368 s.

3. Maurice W., Allan X.R. Guide to Neurology by Adams and Victor. M.: Medical News Agency, 2006. 680 p.

4. A.M. Svyatoshka. Neurosis. A guide for doctors. St. Petersburg: Peter Publishing, 1997.448 s.

5. Guzeva V.I., Mikhailov I.B. Pharmacotherapy of nervous diseases in adults and children. St. Petersburg: Tome, 2002.400 p.

Claims (1)

A method of treating neurosis using pharmaceuticals and additional regenerative procedures, characterized in that mechanically activated amorphous calcium salt of gluconic acid with a homogeneous diffuse halo in its powder X-ray diffraction pattern, characterized by a shift in the center of gravity of the absorption band at 3000-3600 cm ^{-1, is} used as the basic therapy. to the region of large wave numbers by an amount of not more than 200 cm ^-1 , by the presence of an absorption band with frequencies 3308 ± 20, 2933 ± 10, 1602 ± 10, 1420 ± 10 with a shoulder of 1260 ± 40, 1085 ± 10, 1044 ± 10, 877 ± 10, 682 ± 10, 577 ± 10 cm ^-1 and an additional absorption band with a frequency of 947 ± 10 cm ^-1 in the IR spectrum, a decrease in endothermic peaks in the temperature range 125-165 ° C and an increase in peak in the temperature range 30-100 ° c in differential thermal analysis, the presence of a single intensive line with the Lande factor of 2.000 to 2.006 and a width of 8 to 9 E in an electronic paramagnetic resonance spectrum, the appearance of the fine structure unresolved wide line in the regions 60-90 and 170-190 million ^{-1 13} C-NMR spectra shift the resonant lines of their aqueous solutions in 62,8-179,2 mn ^-1 a value of not more than 0.1 million ^{-1 13} C-NMR spectra shift of the resonant lines of their aqueous solutions in 1,2-4,95 mn ^-1 the value of not more than 0.02 million ^{-1 1} H NMR spectra, an increase in the intensities of the peaks of 160 t / g of mass spectra by at least 2.5 times and the peaks of 780-1000 t / g of extracts of their solutions in ethanol by at least three times in the mass spectroscopic analysis orally 1-4 times day, in doses of 0.5-2.0 g for 30-40 days with interruptions in use for 1-2 weeks, in the form of a powder, and / or tablet, and / or capsule, and / or solution, before remission.